Vivos Q2 10-Q: Going Concern Warning, Material Weakness, and FDA IDE Approval
RDGL sits 29% above its 52-week low of $0.043.
Summary
Vivos Inc.'s Q2 2026 10-Q reveals a going concern warning, a material weakness in internal controls, and a $2.0 million net loss, offset by FDA IDE approval for its RadioGel human therapy.
Key Events · Earnings and Guidance · RDGL
-
Going Concern Warning
Cash of $2.34 million is insufficient to cover fixed and variable obligations; company requires approximately $3 million annually to maintain operations.
-
Material Weakness in Controls
Disclosure controls and procedures were ineffective due to a material weakness related to proper segregation of duties.
-
FDA IDE Approval
Received FDA approval in July 2026 for an Early Feasibility Investigational Device Exemption, enabling first-in-human study of RadioGel at Mayo Clinic for non-resectable papillary thyroid carcinoma.
-
Regulation A+ Offering
Raised $2,203,800 in March/April 2026 through sale of 27.2 million shares and 27.8 million warrants.
Analysis · RDGL · Industrial Applications And Services
Vivos Inc. reported a net loss of $2.0 million for the first half of 2026 and disclosed that its cash position is insufficient to support operations, raising substantial doubt about its ability to continue as a going concern. The company also disclosed a material weakness in internal controls due to lack of segregation of duties. On the positive side, the FDA approved an Investigational Device Exemption in July 2026, enabling the first-in-human study of RadioGel at Mayo Clinic. The company raised $2.2 million in March/April 2026 through a Regulation A+ offering, but requires approximately $3 million annually to maintain operations.
At the time of this filing, RDGL was trading at $0.05 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $27M. The 52-week trading range was $0.04 to $0.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.